Oulton Rebekah L, Kohn Tamar, Cwiertny David M
Department of Chemical and Environmental Engineering, University of California, Riverside, A242 Bourns Hall, Riverside, CA 92521, USA.
J Environ Monit. 2010 Nov;12(11):1956-78. doi: 10.1039/c0em00068j. Epub 2010 Oct 12.
Pharmaceuticals and personal care products (PPCPs) represent pollutants of emerging concern, originating in surface and drinking waters largely from their persistence in wastewater effluent. Accordingly, a wealth of recent investigations has examined PPCP fate during wastewater treatment, focusing on their removal during conventional (e.g., activated sludge) and advanced (e.g., ozonation and membrane filtration) treatment processes. Here, we compile nearly 1500 data points from over 40 published sources pertaining to influent and effluent PPCP concentrations measured at pilot- and full-scale wastewater treatment facilities to identify the most effective series of technologies for minimizing effluent PPCP levels. Available data suggest that at best a 1-log(10) concentration unit (90%) of PPCP removal can be achieved at plants employing only primary and secondary treatment, a performance trend that is maintained over the range of reported PPCP influent concentrations (ca. 0.1-10(5) ng L(-1)). Relatively few compounds (15 of 140 PPCPs considered) are consistently removed beyond this threshold at facilities using solids removal and conventional activated sludge (CAS), and most PPCPs are removed to a far lesser extent. Further, increases in CAS hydraulic retention time or sludge retention time do not appreciably increase removal beyond this limit. In contrast, plants employing advanced treatment methodologies, particularly ozonation and/or membranes, remove the vast majority of PPCPs beyond 1-log(10) concentration unit and oftentimes to levels below analytical detection limits in effluent. Data also indicate that passive approaches for tertiary treatment (e.g., wetlands and lagoons) represent promising options for PPCP removal. We conclude by addressing future challenges and frontiers in wastewater management posed by PPCPs including analytical needs for their real-time measurement, energy demands associated with advanced treatment technologies, and byproducts arising from transformation of PPCPs during treatment.
药品和个人护理产品(PPCPs)是新出现的令人担忧的污染物,主要源于其在废水排放中的持久性,从而进入地表水和饮用水中。因此,最近大量的研究调查了PPCPs在废水处理过程中的去向,重点关注其在常规(如活性污泥法)和深度(如臭氧化和膜过滤)处理过程中的去除情况。在此,我们汇总了来自40多个已发表来源的近1500个数据点,这些数据点涉及在中试和全尺寸废水处理设施中测量的进水和出水PPCP浓度,以确定将出水PPCP水平降至最低的最有效技术系列。现有数据表明,仅采用一级和二级处理的工厂,最多只能实现1个对数(10)浓度单位(90%)的PPCP去除,这一性能趋势在所报道的PPCP进水浓度范围内(约0.1 - 10⁵ ng L⁻¹)保持不变。在使用固体去除和传统活性污泥(CAS)的设施中,相对较少的化合物(所考虑的140种PPCPs中的15种)能持续去除超过此阈值,而且大多数PPCPs的去除程度要低得多。此外,CAS水力停留时间或污泥停留时间的增加并不会显著提高去除率,使其超过此限度。相比之下,采用深度处理方法,特别是臭氧化和/或膜处理的工厂,能将绝大多数PPCPs去除超过1个对数(10)浓度单位,而且通常能将出水浓度降至分析检测限以下。数据还表明,三级处理的被动方法(如湿地和泻湖)是去除PPCPs的有前景的选择。我们最后讨论了PPCPs给废水管理带来的未来挑战和前沿问题,包括对其进行实时测量的分析需求、与深度处理技术相关的能源需求,以及处理过程中PPCPs转化产生的副产物。